ReviewHamostaseologie2020
Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis.
Review in Hamostaseologie, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 5 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Mechanisms of pediatric ischemic strokes in COVID-19: a systematic review.Frontiers in stroke · 2023Pooled it
- Recommendations for treatment of critically ill patients with COVID-19 : Version 3 S1 guideline.Der Anaesthesist · 2021Guideline
- A Review of Pathophysiology, Clinical Features, and Management Options of COVID-19 Associated Coagulopathy.Shock (Augusta, Ga.) · 2021Pooled it
- The management of surgical patients in the emergency setting during COVID-19 pandemic: the WSES position paper.World journal of emergency surgery : WJES · 2021Guideline
- [German recommendations for treatment of critically ill patients with COVID-19-version 3 : S1-guideline].Der Anaesthesist · 2020Guideline
- A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection.PloS one · 2023Trial
- The Role of Heparin in Postural Orthostatic Tachycardia Syndrome and Other Post-Acute Sequelae of COVID-19.Journal of clinical medicine · 2024Review
- How to exclude pulmonary embolism in patients hospitalized with COVID-19: a comparison of predictive scores.Thrombosis journal · 2023Article
- Post-COVID Syndrome in Adults-An Overview.Viruses · 2023Review
- Early SARS-CoV-2 infection: Platelet-neutrophil complexes and platelet function.Research and practice in thrombosis and haemostasis · 2023Article
- Thromboembolic events in deceased patients with proven SARS-CoV-2 infection: Frequency, characteristics and risk factors.Thrombosis research · 2022Article
- Thrombosis risk assessment in patients with congenital thrombophilia during COVID - 19 infection.Thrombosis research · 2022Article
- The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1.Journal of thrombosis and haemostasis : JTH · 2022Article
- Increased Susceptibility for Thromboembolic Events versus High Bleeding Risk Associated with COVID-19.Microorganisms · 2022Review
- A comprehensive review of vascular complications in COVID-19.Journal of thrombosis and thrombolysis · 2022Review
- COVID-19 and Vaccine-Induced Thrombosis.Tanaffos · 2022Review
- First report from the German COVID-19 autopsy registry.The Lancet regional health. Europe · 2022Article
- Review of Case Study: Chowdhry, Moshman, and Caroll (2021). A Case of COVID-19 Related Coagulopathy Complications and Heparin Resistance.Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing · 2022Article
- Article
- Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer.Cancer discovery · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The novel coronavirus, SARS-CoV-2, is causing a global pandemic of life-threatening multiorgan disease, called COVID-19. Accumulating evidence indicates that patients with COVID-19 are at significant risk of thromboembolic complications, mainly affecting the venous, but also the arterial vascular system. While the risk of venous thromboembolism (VTE) appears to be higher in patients requiring intensive care unit support compared to those admitted to general wards, recent autopsy findings and data on the timing of VTE diagnosis relative to hospitalization clearly suggest that thromboembolic events also contribute to morbidity and mortality in the ambulatory setting. In addition to a severe hypercoagulable state caused by systemic inflammation and viral endotheliitis, some patients with advanced COVID-19 may develop a coagulopathy, which meets established laboratory criteria for disseminated intravascular coagulation, but is not typically associated with relevant bleeding. Similar to other medical societies, the Society of Thrombosis and Haemostasis Research has issued empirical recommendations on initiation, dosing, and duration of pharmacological VTE prophylaxis in COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.